05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
pharmaceutical and medical preparations; Pharmaceutical preparations for the treatment of allergies; Pharmaceutical preparations for the treatment of allergic rhinitis; dietetic substances adapted for medical use. medical apparatus and instruments.
3.
PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS
The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.
A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Soaps; perfumery; essential oils; cosmetics. Pharmaceutical and veterinary preparations; Pharmaceutical preparations for the treatment of allergies; Pharmaceutical preparations for the treatment of allergic rhinitis; sanitary preparations for medical use; sanitary preparations and articles; dietetic substances adapted for medical use; plasters, materials for dressings; disinfectants. medical apparatus and instruments.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical preparations for the treatment and prevention of allergies; Pharmaceutical preparations for the treatment and prevention of allergic rhinitis; dietetic substances adapted for treatment and prevention of allergies. medical apparatus and instruments.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Non-medicated cosmetics and toiletry preparation. pharmaceutical and medical preparations; Pharmaceutical preparations for the treatment of allergies; Pharmaceutical preparations for the treatment of allergic rhinitis; dietetic substances adapted for medical use. medical apparatus and instruments.
The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease. The neurodegenerative disease is a disease selected from the group consisting of Alzheimer's disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, prion diseases, HIV-associated dementia and any form of cognitive disorders linked to neurodegeneration, preferably Alzheimer's disease,
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Non-medicated cosmetics and toiletry preparation. pharmaceutical and medical preparations; Pharmaceutical preparations for the treatment of allergies; Pharmaceutical preparations for the treatment of allergic rhinitis; dietetic substances adapted for medical use. medical apparatus and instruments.
10.
Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof
The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6-azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula (VIII) using a Wittig reagent in a suitable solvent; v) reacting through the Makosza reaction the compound of Formula (VIII) using bromoform and a suitable base to obtain cyclopropane compound of Formula (IX); and vi) removing bromine atoms in the presence of a reducing agent and a base in an alcoholic solvent thus obtaining (SM1). The invention relates also to a process for the conversion of the compound (SM1) for preparing (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid (IV) or a salt thereof. The salt is preferably the sodium salt, more preferably the polymorphic form A of sodium (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ+0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9.
The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro [2.5]octane-5-carboxamido)cyclopropyl)benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro [2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4458 - Non-condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention relates to a N-phenylcarbamoyl compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the inhibition of at least one of tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and disorders involved with one or both kinases.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossification
There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
14.
USE OF 2-PHENYL-6-(1H-IMIDAZOL-1-YL) QUINAZOLINE FOR THE PREVENTION OF ABUSE AND OF SIDE EFFECTS OF AT LEAST ONE OPIOID
The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ+0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF
The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula (VIII) using a Wittig reagent in a suitable solvent; v) reacting through the Makosza reaction the compound of Formula (VIII) using bromoform and a suitable base to obtain cyclopropane compound of Formula (IX); and vi) removing bromine atoms in the presence of a reducing agent and a base in an alcoholic solvent thus obtaining (SM1). The invention relates also to a process for the conversion of the compound (SM1) for preparing (R)- 4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid (IV) or a salt thereof. The salt is preferably the sodium salt, more preferably the polymorphic form A of sodium (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6- azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2? ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9.
PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF
The present invention provides a process for preparing (R)-6-(tert-butoxycarbonyl)-6- azaspiro[2.5]octane-5-carboxylic acid (SM1), said process comprising the step of: iv) converting a compound of formula (VII) into a compound of formula (VIII) using a Wittig reagent in a suitable solvent; v) reacting through the Makosza reaction the compound of Formula (VIII) using bromoform and a suitable base to obtain cyclopropane compound of Formula (IX); and vi) removing bromine atoms in the presence of a reducing agent and a base in an alcoholic solvent thus obtaining (SM1). The invention relates also to a process for the conversion of the compound (SM1) for preparing (R)- 4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid (IV) or a salt thereof. The salt is preferably the sodium salt, more preferably the polymorphic form A of sodium (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6- azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9.
The invention relates to a N-phenylcarbamoyl compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the inhibition of at least one of tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and disorders involved with one or both kinases. (Formula)
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The invention relates to a N-phenylcarbamoyl compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the inhibition of at least one of tyrosine kinase selected from Fyn and VEGFR2 in the treatment of diseases and disorders involved with one or both kinases.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The present invention relates to a compound of formula 2-phenyl-6-(1H-imidazol-1-yl) quinazoline (CR4056) or a pharmaceutically acceptable salt thereof for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid. The invention also relates to a composition or a pharmaceutical kit comprising a compound of formula 2-phenyl-6-(1Himidazol-1-yl) quinazoline (CR4056) or one of its pharmaceutically acceptable salts and at least one opioid for use in the prevention of abuse in an opioid non-addicted subject and other side effects of at least one opioid.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
23.
(R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR ITS SALT ALSO IN POLYMORPHIC FORM A FOR USE IN THE PREVENTION OF HETEROTOPIC OSSIFICATION
There is described a compound of formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)- cyclopropyl)benzoic acid or a pharmaceutically acceptable salt thereof or the form A of its sodium salt for use in the prevention of heterotopic ossification. Preferably such a compound is effective in a specific dose range.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
24.
(R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist
The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
The invention concerns a compound of formula 2-phenyl-6-(1H-imidazol-1-yl)quinazoline or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease. The neurodegenerative disease is a disease selected from the group consisting of Alzheimer's disease, Lewy body dementia, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington disease, prion diseases, HIV-associated dementia and any form of cognitive disorders linked to neurodegeneration, preferably Alzheimer's disease.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
28.
BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS
The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
29.
PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2)
125653678781343336366)cycloalkyl and an optionally substituted unsaturated heterocyclic ring for use as a medicament. The compounds as medicament are used in the treatment (DDR2)-mediated diseases and disorders such as a cancer, acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, atherosclerosis, various fibrotic disorders, fibrosis or kidney injury.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/04 - Centrally acting analgesics, e.g. opioids
The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5- carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1- (6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2θ ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 31/00 - Medicinal preparations containing organic active ingredients
31.
PHARMACEUTICAL COMBINATION OF AN EP4 ANTAGONIST AND IMMUNE CHECKPOINT INHIBITORS FOR THE TREATMENT OF TUMOURS
The present invention provides a pharmaceutical combination comprising the EP4 antagonist of Formula (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5- carboxamido)cyclopropyl)-benzoic acid or a pharmaceutically acceptable salt thereof and at least one immune checkpoint inhibitor, preferably the sodium salt of (R)-4-(1- (6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl) benzoic acid. A polymorphic form A of sodium salt of (R)-4-(1-(6-(4-(trifluoromethyl) benzyl)-6-azaspiro[2.5]octane-5-carboxamido)cyclopropyl)benzoate characterized by a powder XRD spectrum with peaks at values of the angle 2? ±0.2° of 4.3, 5.0, 5.8, 6.4, 7.1, 8.3, 8.7, 12.8, 15.3, 15.9 is also described. The combination and the polymorphic form A are described for use in the treatment of tumours.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
32.
PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2)
12563677 134 33 13366)cycloalkyl and unsaturated heterocyclic ring. The compounds are used in the treatment (DDR2)-mediated diseases and disorders such as a cancer, acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, atherosclerosis, various fibrotic disorders or kidney injury.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/04 - Centrally acting analgesics, e.g. opioids
The invention relates to a liquid oral care composition that is a mouthwash, mouthrinse or a spray comprising: - 0.005 to 1% w/w chlorhexidine or a salt thereof; - arginine or a salt thereof; and - a zincsalt. The invention also relates to the use of arginineor a salt thereof for stabilising chlorhexidine or a salt thereof in a liquid oral care compositionthat is amouthwash, mouthrinse or a spray.
A liquid oral care composition comprising: • a galactooligosaccharide; and • xylitol; for use in the treatment or prophylaxis of an oral bacterial infection.
The invention relates to topical formulations comprising: a galactooligosaccharide; 0.01% to 10% w/w xylitol; and a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
The present disclosure is directed to an improved process to convert crude ascomycin to purified pimecrolimus. Crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus, which is then purified further by HPLC and subsequent crystallization. The processes of the present disclosure enable the removal of close homologs of pimecrolimus by high-pressure liquid chromatography without prior purification of the ascomycin starting material. This improvement may make the conversion of ascomycin to pimecrolimus industrially applicable and less expensive.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals and natural remedies; pharmaceutical and medical preparations; Pharmaceutical preparations for the treatment of allergies; Pharmaceutical preparations for the treatment of allergic rhinitis; sanitary preparations for medical use; sanitary preparations and articles; dietetic substances adapted for medical use, plasters, materials for dressings; disinfectants. medical apparatus and instruments.
38.
(R)-4-(1-(1-(4-(TRIFLUOROMETHYL)BENZYL)PYRROLIDINE-2-CARBOXAMIDE)CYCLOPROPYL)-BENZOIC ACID AS EP4 RECEPTOR ANTAGONIST
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, substances and products for the
treatment of cardiovascular disorders and/or diseases;
pharmaceutical preparations, substances and products for the
treatment of hyperlipidemia; pharmaceutical preparations,
substances and products for the treatment of
hypercholesterolemia.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; medical preparations; pharmaceutical
preparations; pharmaceutical products for medical use;
dietetic substances for medical use; diagnostic substances
for medical use; pharmaceutical products and substances for
the treatment of cardiovascular disorders and/or diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals; medical preparations; pharmaceutical
preparations; pharmaceutical products for medical use;
dietetic substances for medical use; diagnostic substances
for medical use; pharmaceutical products and substances for
the treatment of cardiovascular disorders and/or diseases.
The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 9/00 - Medicinal preparations characterised by special physical form
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceuticals; medical preparations; pharmaceutical preparations; pharmaceutical products for medical use; dietetic substances for medical use; diagnostic substances for medical use; pharmaceutical products and substances for the treatment of cardiovascular disorders and/or diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceuticals; medical preparations; pharmaceutical preparations; pharmaceutical products for medical use; dietetic substances for medical use; diagnostic substances for medical use; pharmaceutical products and substances for the treatment of cardiovascular disorders and/or diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
pharmaceutical preparations, substances and products for the treatment of cardiovascular disorders and/or diseases; pharmaceutical preparations, substances and products for the treatment of hyperlipidemia; pharmaceutical preparations, substances and products for the treatment of hypercholesterolemia.
46.
ANTIBACTERIAL ACTIVITY OF GALACTOOLIGOSACCHARIDE AND XYLITOL IN DERMATOLOGICAL TREATMENTS
The invention relates to topical formulations comprising: • a galactooligosaccharide; • 0.01 % to 10% w/w xylitol; and • a pharmaceutically or cosmetically acceptable carrier. The invention also relates to use of the formulations, and methods for their preparation.
A61Q 17/00 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
The present disclosure is directed to an improved process to convert crude ascomycin to purified pimecrolimus. Crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus, which is then purified further by HPLC and subsequent crystallization. The processes of the present disclosure enable the removal of close homologs of pimecrolimus by high-pressure liquid chromatography without prior purification of the ascomycin starting material. This improvement may make the conversion of ascomycin to pimecrolimus industrially applicable and less expensive.
The present disclosure is directed to an improved process to convert crude ascomycin to purified pimecrolimus. Crude ascomycin is chlorinated with triphenylphosphine and N-chlorosuccinimide (NCS) to yield crude pimecrolimus, which is then purified further by HPLC and subsequent crystallization. The processes of the present disclosure enable the removal of close homologs of pimecrolimus by high-pressure liquid chromatography without prior purification of the ascomycin starting material. This improvement may make the conversion of ascomycin to pimecrolimus industrially applicable and less expensive.
The present invention relates to a kit for administration of medicaments. The kit comprises a box (1) that contains at least one medicament delivery device (4, 4a) and a video device (3). The video device (3) may be configured to provide visual or audio-visual instructions for using the medicament delivery device (4, 4a). Both the at least one medicament delivery device (4, 4a) and the video device (3) are removably attached to the box (1). Removal of the at least one medicament delivery device (4, 4a) and the video device (3) from the box (1) allows carrying the at least one medicament delivery device (4, 4a) and the video device (3) without the need to carry the entire box (1). As carrying the at least one medicament delivery device (4, 4a) and the video device (3) without the box (1) is much more comfortable as compared to carrying the entire bulky box (1) it is more likely as compared to the prior art that the patient will indeed carry the medicament delivery device (4, 4a) at all times so that the medicament delivery device (4, 4a) is available when needed. Moreover, as the video device can be removed from the bulky box (1) it is more likely as compared to the prior art that the patient will also carry the video device (3). Thus, the likelihood of improper use of the medicament delivery device (4, 4a) is decreased as compared to the prior art.
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 25/04 - Centrally acting analgesics, e.g. opioids
The invention relates to a composition having antimicrobial and hygroscopic properties and the composition comprises a carboxylic acid compound as well as at least one C3-C6 diol and at least one C8-C12 diol. The composition of the invention may be used for cleansing, disinfection, surface treatment, impregnation and for antimicrobial treatment. The composition is particularly useful for treatment of fungal infections of the nail (onychomycosis).
A01N 37/36 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio-analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
Goods & Services
(1) Mouthwash; non-medicated anti-cavity mouthwash; mouth rinse; non-medicated anti-cavity mouth rinse; breath fresheners, namely breath freshening strips; dentifrices; tooth-powder; toothpaste.
(2) Medicated mouthwash; medicated anti-cavity mouthwash; medicated mouth rinse; medicated anti-cavity mouth rinse; medicated toothpaste; medicated chewing gum for the treatment of bad breath and for mouth freshness; medicated throat lozenges, medicated lozenges for the treatment of bad breath and for mouth freshness. (1) Retail or wholesale services for pharmaceutical, veterinary and sanitary preparations and medical supplies.
The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.
A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61Q 17/02 - Barrier preparationsPreparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
58.
PUMP CAP FOR A PHARMACEUTICAL CONTAINER, INSERT FOR A PUMP CAP FOR A PHARMACEUTICAL CONTAINER, PHARMACEUTICAL CONTAINER WITH THE PUMP CAP, AND COMPUTER PROGRAM PRODUCT
In a pump cap for a pharmaceutical container, the pump cap accommodates an electronics unit which is designed to detect an actuation of the pump cap by a user in order to dispense content from the container, to wirelessly output signals representing actuations of the pump cap, and to have operating energy for detecting one or more actuations of the pump cap by a user and for wirelessly outputting signals representing the one or more actuations of the pump cap wirelessly delivered to it from outside by an electronic appliance in the form of a personal digital assistant.
The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention describes a cosmetic or dermatological composition for use in the antibacterial and/or anti-inflammatory treatment comprising a combination of vegetal extracts titrated in salicin and 1,2-alkanediols, preferably 1, 2-decanediol and willow bark (Salix alba) extract.
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 36/76 - Salicaceae (Willow family), e.g. poplar
The invention describes the preparation of new cocoa bean extracts and their use in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of physical and mental frailty and weakness.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
64.
PURIFIED COCOA BEANS AND GRAPE SEEDS EXTRACTS, PRODUCTION AND USE THEREOF FOR THE TREATMENT OF CENTRAL AND PERIPHERIC HUMAN DISEASES
The invention describes the preparation of new cocoa bean and grape seed extracts and their use, and use of their mixtures in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of physical and mental frailty and weakness.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
65.
PURIFIED GRAPE SEEDS EXTRACTS, PRODUCTION AND USE THEREOF FOR THE TREATMENT OF CENTRAL AND PERIPHERIC HUMAN DISEASES
The invention describes the preparation of new grape seed extracts and their use in the treatment of various human pathological conditions, such as vascular diseases, cognitive disorders, depressive disturbances or clinical pictures of physical and mental frailty and weakness.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Soaps namely skin soaps, facial soaps; cosmetics namely, face cream, skin cream, moisturizing cream, creams and lotions for improving the clarity of skin.
(2) Antiseptic facial creams and lotions, antiseptic skin creams and lotions, antiseptic creams and lotions for treatment of acne; dietary supplements for humans for promotion of general health and well being and for improving complexion; acne treatment for improving the clarity of skin.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Soaps namely skin soaps, facial soaps; cosmetics namely, face cream, skin cream, moisturizing cream, creams and lotions for improving the clarity of skin.
(2) Antiseptic facial creams and lotions, antiseptic skin creams and lotions, antiseptic creams and lotions for treatment of acne; acne treatment for improving the clarity of skin.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Soaps namely skin soaps, facial soaps; cosmetics namely, face cream, skin cream, moisturizing cream, acne treatment, creams and lotions for improving the clarity of skin, antiseptic facial creams and lotions, antiseptic skin creams and lotions, antiseptic creams and lotions for the treatment of acne; Dietary supplements for humans for promotion of general health and well being and for improving complexion.
The present invention relates to a composition comprising an antibacterial agent in an amount insufficient to provide antibacterial effect, a physiologically acceptable divalent metal ion in a very low concentration and a physiologically acceptable polymer for preventing and/or treating halitosis, bad breath, dry mouth or sore throat.
The present invention relates to a composition of pH in the range 2.0 to 4.5 comprising at least one fluoride source and at least one other agent for use in prevention and/or treatment of dental erosion.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Bleaching preparations for laundry use; soaps for personal use; perfumery, essential oils for personal use and essential oils for the manufacture of perfumes, cosmetics, hair lotions; dentifrices; face and body creams, face and body washing detergents and face and body emulsions, skin creams and skin cleaner
(2) Cosmetics, namely, face and body creams, skin creams and skin cleanser; soaps, namely, face and body washing detergents and face and body emulsions
(3) Pharmaceutical preparations for the treatment of skin irritations, namely, rashes, redness, bee stings, insect bites and dry skin; pharmaceutical preparations for the treatment of skin diseases namely, dermatitis and eczema; medications for moisturizing dry skin; pharmaceutical preparations for use in dermatology, namely for treating and alleviating symptoms of eczema and dermatitis; dietary supplements for humans for general health and wellbeing, food for babies; medical and surgical plasters; material for stopping teeth, dental wax; all purpose disinfectants; disinfecting handwash; disinfectants for hygiene purposes; disinfectants for medical instruments; preparations for destroying vermin; fungicides, herbicides
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations; sanitary preparations for medical purposes; dietary supplements; pharmaceutical preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical use; all the afore-mentioned goods not for use in animals.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Medication for the elimination of nasal secretions; medicinal salts for rinsing, inhaling and gargling; pharmaceutical preparations, namely, isotonic solution for the ear and nose; sanitary preparations for medical purposes namely isotonic solutions for treating otological and respiratory disorders, colds, cough, allergic rhinitis, rhinitis, sinusitis, rhinosinusitis, dental diseases, oral diseases, hoarseness, congestion and heartburn.
(2) Medical devices, namely, applicators for humidifying, cleaning and moisturizing nasal cavities and ear canals, apparatus for nasal and aural rinse; irrigators for medical use.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; hygienic
preparations for medical purposes; dietetic substances for
medical purposes; food for babies; plasters, materials for
dressings; material for stopping teeth, dental wax;
disinfectants. Surgical, medical, dental and veterinary apparatus and
instruments, artificial limbs, eyes and teeth; orthopedic
articles.
4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases.
2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.
C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 209/52 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 453/06 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing iso-quinuclidine ring systems
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely bisphosphonates (also called diphosphonates); vitamin preparations; mineral food supplements; dietetic food and substances adapted for medical use; dietary supplements for humans.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations, namely bisphosphonates (also called diphosphonates); vitamin preparations; mineral food supplements; dietetic food and substances adapted for medical use; dietary supplements for humans.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
chemical and biochemical substances; enzymes; nucleic acid sequences; viral vectors; non-viral vectors; plasmids; cloning vehicles; micro-organisms; cultures of micro-organisms and chemical products for in-vitro and in vivo use in laboratories and for analysis; viruses; cell cultures; chemical products for in vitro or in vivo use in biotechnology, and research and development; Chemicals used in industry and biochemical products and antibodies used in industry and in science. Soaps for personal use; perfumery; essential oils; dentifrices; cleaning, polishing, scouring and abrasive preparations none of which for laundry use; Hair lotions. Biochemical substances and preparations for medical purposes; therapeutic and prophylactic pharmaceutical and biochemical products; gene therapy products; viral, retroviral and non-viral vectors; viral, retroviral and non-viral vector manufacturing preparations; plasters; material for dressing; material for stopping teeth; dental wax; disinfectants for human and veterinary use; preparations for destroying vermin; fungicides; herbicides; Antibodies; Sanitary preparations for medical purposes; Dietary supplements for humans and animals; vaccines; small molecules; biologics; enzymes and enzyme preparations; pharmaceuticals for the delivery of genes to cells; all for medical purposes. Surgical, medical, dental and veterinary apparatus and instruments; including instruments and apparatus for the administration of pharmaceutical and biochemical products; gene therapy and/or vaccine preparations and substances, pre-filled vials; syringes and injectors for medical purposes; artificial limbs; eyes and teeth; orthopedic articles; suture materials. Education; providing of training; cultural and scientific education; arranging or conducting conferences and congresses. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer software for medical and scientific applications. Medical services; veterinary services; hygienic and beauty care for human beings or animals; medical and scientific advisory; diagnostics.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
chemical and biochemical substances; enzymes; nucleic acid sequences; viral vectors; non-viral vectors; plasmids; cloning vehicles; micro-organisms; cultures of micro-organisms and chemical products for in-vitro and in vivo use in laboratories and for analysis; viruses; cell cultures; chemical products for in vitro or in vivo use in biotechnology, and research and development; Chemicals used in industry and biochemical products and antibodies used in industry and in science. Soaps; perfumery; essential oils; dentifrices; bleaching preparations and other substances for laundry use; cleaning, polishing, scouring and abrasive preparations; Hair lotions. biochemical substances and preparations for medical purposes; therapeutic and prophylactic pharmaceutical and biochemical products; gene therapy products; viral, retroviral and non-viral vectors; viral, retroviral and non-viral vector manufacturing preparations; plasters; material for dressing; material for stopping teeth; dental wax; disinfectants; preparations for destroying vermin; fungicides; herbicides; Antibodies; Sanitary preparations for medical purposes; Dietary supplements for humans and animals; vaccines; small molecules; biologics; enzymes and enzyme preparations; pharmaceuticals for the delivery of genes to cells; all for medical purposes. Surgical, medical, dental and veterinary apparatus and instruments; including instruments and apparatus for the administration of pharmaceutical and biochemical products; gene therapy and/or vaccine preparations and substances, pre-filled vials; syringes and injectors for medical purposes; artificial limbs; eyes and teeth; orthopedic articles; suture materials. Education; providing of training; cultural and scientific education; arranging or conducting conferences and congresses. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer software for medical and scientific applications; none of the aforesaid services relating to vehicles, engines, parts and subassemblies thereof and materials for use therein. Medical services; veterinary services; hygienic and beauty care for human beings or animals; medical and scientific advisory; diagnostics.
01 - Chemical and biological materials for industrial, scientific and agricultural use
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
chemical and biochemical substances; enzymes; nucleic acid sequences; viral vectors; non-viral vectors; plasmids; cloning vehicles; micro-organisms; cultures of micro-organisms and chemical products for in-vitro and in vivo use in laboratories and for analysis; viruses; cell cultures; chemical products for in vitro or in vivo use in biotechnology, and research and development; Chemicals used in industry and biochemical products and antibodies used in industry and in science. Soaps for personal use; perfumery; essential oils; dentifrices; cleaning, polishing, scouring and abrasive preparations none of which for laundry use; Hair lotions. Biochemical substances and preparations for medical purposes; therapeutic and prophylactic pharmaceutical and biochemical products; gene therapy products; viral, retroviral and non-viral vectors; viral, retroviral and non-viral vector manufacturing preparations; plasters; material for dressing; material for stopping teeth; dental wax; disinfectants for human and veterinary use; preparations for destroying vermin; fungicides; herbicides; Antibodies; Sanitary preparations for medical purposes; Dietary supplements for humans and animals; vaccines; small molecules; biologics; enzymes and enzyme preparations; pharmaceuticals for the delivery of genes to cells; all for medical purposes. Surgical, medical, dental and veterinary apparatus and instruments; including instruments and apparatus for the administration of pharmaceutical and biochemical products; gene therapy and/or vaccine preparations and substances, pre-filled vials; syringes and injectors for medical purposes; artificial limbs; eyes and teeth; orthopedic articles; suture materials. Education; providing of training; cultural and scientific education; arranging or conducting of conferences and congresses. Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer software for medical and scientific applications. Medical services; veterinary services; hygienic and beauty care for human beings or animals; medical and scientific advisory; diagnostics.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Mouthwash; anti-cavity mouthwash; mouth rinse; anti-cavity mouth rinse; breath fresheners, namely chewing gum; pharmaceutical preparations for prophylaxis of halitosis and bad breath; pharmaceutical preparations for treatment of halitosis and bad breath; sanitary preparations for medical purposes, namely, medicated liquids for the treatment of bad breath and halitosis; medicated mouthwash for prophylaxis of halitosis and bad breath; medicated mouthwash for the treatment of halitosis and of bad breath; medicated mouthwash for the treatment of bad breath; medicated anti-cavity mouthwash; medicated mouth rinse for the treatment of halitosis and bad breath; medicated anti-cavity mouth rinse; medicated chewing gum for the treatment of halitosis and bad breath; medicated chewing gum for the prophylaxis of halitosis and bad breath.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Breath fresheners, namely chewing gum; pharmaceutical preparations for prophylaxis of halitosis and bad breath; pharmaceutical preparations for treatment of halitosis and bad breath; medicated chewing gum for the treatment of halitosis and bad breath; medicated chewing gum for the prophylaxis of halitosis and bad breath.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Breath fresheners, namely chewing gum; pharmaceutical preparations for prophylaxis of halitosis and bad breath; pharmaceutical preparations for treatment of halitosis and bad breath; medicated chewing gum for the treatment of halitosis and bad breath; medicated chewing gum for the prophylaxis of halitosis and bad breath.
89.
ANTI-ADAMTS-5 ANTIBODY, DERIVATIVES AND USES THEREOF
The present invention relates to an antibody,recombinant or synthetic antigen-binding fragments thereof able to recognise and bind an epitope comprised in the spacer domain of ADAMTS-5, nucleic acid and expression vector encoding the same, method of production and uses thereof.
The present invention provides compounds of formula (I) including stereoisomers or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein X is NH, or O; Q is 5-6 membered heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; A is phenyl or a 5-6 heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; B may assume different meanings from A and is phenyl or a 5-6 membered heteroaryl group, which may be substituted by one or more substituents independently selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; and processes for their preparation, pharmaceutical compositions containing them and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 25/00 - Drugs for disorders of the nervous system
The invention, in a first aspect relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R is a 6-membered aromatic ring, or a 5- or 6-membered heteroaromatic ring comprising 1 to 3 heteroatoms selected from S, O and N, or a 6-membered benzocondensed heteroaromatic ring containing N as heteroatom, optionally each of said rings being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl, cyano, trifluoromethyl, dimethylamino, or phenyl which optionally is substituted with one or more halogen atoms, or a 5- or 6-membered heterocycle containing from one to three nitrogen atoms; X is O or N; P is pyridyl, pyrimidyl, pyrazyl, or pyridazyl, each being optionally substituted with one or more substituents selected from the group consisting of (C1-C3)alkyl, halogen, trifluoromethyl, and cyano, and use thereof as pharmaceuticals.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61P 25/00 - Drugs for disorders of the nervous system
The invention relates to drug preparations with controlled active ingredient released in the form of microtablets which contain, as active ingredient, flupirtin or one of its physiologically compatible salts, and to processes for their production.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Bleaching preparations and other substances for laundry use; Cleaning, polishing, scouring and abrasive preparations; Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; Apparatus and instruments containing pharmaceutical preparations, substances and medicines, parts and fittings thereof, included in class 5; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants. Surgical, medical, dental and veterinary apparatus and instruments; parts and fittings of surgical, medical, dental and veterinary apparatus and instruments, included in class 10.
The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4427 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Food for babies; Dietary supplements for humans and animals; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Soaps; essential oils, cosmetics. Pharmaceutical preparations; sanitary preparations for medical use; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; Orthopedic articles; Suture materials.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; Orthopedic articles; Suture materials.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Soaps; Perfumery, essential oils, cosmetics, hair lotions; Dentifrices. Pharmaceutical and veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use, food for babies; Dietary supplements for humans and animals; Plasters, materials for dressings; Material for stopping teeth, dental wax; Disinfectants; Preparations for destroying vermin; Fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments, artificial limbs, eyes and teeth; Orthopedic articles; Suture materials.
